Find information on thousands of medical conditions and prescription drugs.

Zonegran

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

Read more at Wikipedia.org


[List your site here Free!]


Eisai
From Drug Store News, 5/17/04 by James Frederick

Supplier News--Eisai last month closed the deal on acquiring the epilepsy treatment Zonegran (zonisamide) from Elan Pharma.

As part of the agreement, Eisai acquired exclusive North American and European manufacturing, development and marketing rights to Zonegran.

Financial terms were not disclosed. Zonegran generated $80.7 million in U.S. sales in 2003.

The acquisition represents Eisai's third agreement in the epilepsy arena. In February, Eisai in-licensed rufinamide from Novartis Pharma, and in 2002, Eisai acquired the exclusive rights to promote Pfizer's Cerebyx (fosphenytoin sodium injection).

Another anticipated addition to Eisai's neurology product line results from a May 2003 agreement with Teva for the co-development of rasagiline for Alzheimer's disease and co-promotion in the United States for Parkinson's disease, if the Food and Drug Administration approves the drug.

COPYRIGHT 2004 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2004 Gale Group

Return to Zonegran
Home Contact Resources Exchange Links ebay